Pertussis (Whooping Cough) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H2 2016, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape.

Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pertussis (Whooping Cough) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12, 3, 5, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 3 molecules, respectively.

Pertussis (Whooping Cough) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pertussis (Whooping Cough) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pertussis (Whooping Cough) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pertussis (Whooping Cough) Overview 8
Therapeutics Development 9
Pipeline Products for Pertussis (Whooping Cough) - Overview 9
Pipeline Products for Pertussis (Whooping Cough) - Comparative Analysis 10
Pertussis (Whooping Cough) - Therapeutics under Development by Companies 11
Pertussis (Whooping Cough) - Therapeutics under Investigation by Universities/Institutes 13
Pertussis (Whooping Cough) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Pertussis (Whooping Cough) - Products under Development by Companies 17
Pertussis (Whooping Cough) - Products under Investigation by Universities/Institutes 19
Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development 20
Beijing Minhai Biotechnology Co Ltd 20
Beijing Tiantan Biological Products Co Ltd 21
Bharat Biotech International Ltd 22
Biken Inc 23
Biological E Ltd 24
Boryung Pharmaceutical Co Ltd 25
Daiichi Sankyo Company Ltd 26
DBV Technologies SA 27
GlaxoSmithKline Plc 28
Green Cross Corp 29
ILiAD Biotechnologies LLC 30
Indian Immunologicals Ltd 31
Kaketsuken KK 32
LG Life Science LTD 33
NanoBio Corp 34
Panacea Biotec Ltd 35
Sanofi Pasteur SA 36
Serum Institute of India Ltd 37
Shantha Biotechnics Ltd 38
Synthetic Biologics Inc 39
Zydus Cadila Healthcare Ltd 40
Pertussis (Whooping Cough) - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 49
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 50
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 51
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 52
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 53
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 54
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 55
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 56
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 57
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 58
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 59
(diphtheria + haemophilus influenzae [serotype B] + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile 60
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 61
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 62
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 63
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 64
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 65
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile 66
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile 67
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 68
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 69
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 70
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 72
(hepatitis B + pertussis) vaccine - Drug Profile 73
bladder cancer + pertussis + tuberculosis vaccine - Drug Profile 74
BVN-002 - Drug Profile 75
Eupenta - Drug Profile 76
GC-3111A - Drug Profile 77
KD-370 - Drug Profile 78
LBVD - Drug Profile 79
pertussis (acellular) vaccine - Drug Profile 80
pertussis (acellular) vaccine - Drug Profile 81
pertussis (whole cell) vaccine - Drug Profile 82
pertussis [strain BPZE1] vaccine - Drug Profile 83
pertussis vaccine - Drug Profile 85
pertussis vaccine - Drug Profile 86
pertussis vaccine - Drug Profile 87
SYN-005 - Drug Profile 89
VN-0103 - Drug Profile 91
VN-0105 - Drug Profile 92
Pertussis (Whooping Cough) - Dormant Projects 93
Pertussis (Whooping Cough) - Discontinued Products 95
Pertussis (Whooping Cough) - Product Development Milestones 96
Featured News & Press Releases 96
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H2 2016 12
Number of Products under Development for Pertussis (Whooping Cough) - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Pertussis (Whooping Cough) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 23
Pertussis (Whooping Cough) - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2016 24
Pertussis (Whooping Cough) - Pipeline by Bharat Biotech International Ltd, H2 2016 25
Pertussis (Whooping Cough) - Pipeline by Biken Inc, H2 2016 26
Pertussis (Whooping Cough) - Pipeline by Biological E Ltd, H2 2016 27
Pertussis (Whooping Cough) - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 28
Pertussis (Whooping Cough) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 29
Pertussis (Whooping Cough) - Pipeline by DBV Technologies SA, H2 2016 30
Pertussis (Whooping Cough) - Pipeline by GlaxoSmithKline Plc, H2 2016 31
Pertussis (Whooping Cough) - Pipeline by Green Cross Corp, H2 2016 32
Pertussis (Whooping Cough) - Pipeline by ILiAD Biotechnologies LLC, H2 2016 33
Pertussis (Whooping Cough) - Pipeline by Indian Immunologicals Ltd, H2 2016 34
Pertussis (Whooping Cough) - Pipeline by Kaketsuken KK, H2 2016 35
Pertussis (Whooping Cough) - Pipeline by LG Life Science LTD, H2 2016 36
Pertussis (Whooping Cough) - Pipeline by NanoBio Corp, H2 2016 37
Pertussis (Whooping Cough) - Pipeline by Panacea Biotec Ltd, H2 2016 38
Pertussis (Whooping Cough) - Pipeline by Sanofi Pasteur SA, H2 2016 39
Pertussis (Whooping Cough) - Pipeline by Serum Institute of India Ltd, H2 2016 40
Pertussis (Whooping Cough) - Pipeline by Shantha Biotechnics Ltd, H2 2016 41
Pertussis (Whooping Cough) - Pipeline by Synthetic Biologics Inc, H2 2016 42
Pertussis (Whooping Cough) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 43
Assessment by Monotherapy Products, H2 2016 44
Assessment by Combination Products, H2 2016 45
Number of Products by Stage and Target, H2 2016 47
Number of Products by Stage and Route of Administration, H2 2016 49
Number of Products by Stage and Molecule Type, H2 2016 51
Pertussis (Whooping Cough) - Dormant Projects, H2 2016 96
Pertussis (Whooping Cough) - Dormant Projects (Contd..1), H2 2016 97
Pertussis (Whooping Cough) - Discontinued Products, H2 2016 98